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Abstract
Epidemiological evidence demonstrates that smoking is the most important environmental risk
factor in Crohn's disease while it positively interferes with the disease course of ulcerative coli-
tis. However, the underlying mechanisms through which smoking exerts this divergent effect and
affects pathogenesis of inflammatory bowel disease are largely unknown. Animal smoke models
are good models to investigate the impact of cigarette smoke on intestinal physiology and
inflammation. They enable one to explore the interaction of smoke components and the
gut on cellular and molecular level, clarifying how smoking interferes with normal gut func-
tion and with disease course in inflammatory conditions. This review describes the currently
used animal models for studying the impact of cigarette smoke on the intestinal tract. We
first discuss the different methods for simulation of smoking. Furthermore, we focus on
the effect of smoke exposure on normal gut physiology and immunology, on experimental
(entero)colitis, and on inflammation-induced neoplasia. Based on this current knowledge,
a hypothesis is formulated about the mechanisms through which cigarette smoke interferes
with the gut in normal and pathological conditions.
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The relationship between smoking and inflammatory bowel
disease (IBD) is well recognized since many years. Cigarette
smoke is considered to be the most important environmental
risk factor in IBD pathogenesis. The first reports underscor-
ing its role in IBD date from 30 years ago.1,2 Since then, a
large number of epidemiological studies described the dual
effect of (active) smoking: it is associated with a higher
risk for developing Crohn's disease (CD) and a worse outcome
in CD patients, whereas ulcerative colitis (UC) is primarily
a disease of non-smokers and smoking and nicotine are as-
sumed to play a protective role in UC.3,4 The ethnic back-
ground of patients also interferes with the effect of
smoking on IBD. Most studies were performed in a Caucasian
population; however, several epidemiological studies per-
formed in Israel failed to find an association between smok-
ing and Crohn's disease in Jewish patients.5,6 More recently,
also passive smoking was investigated as potential risk factor
for IBD. However, a large meta-analysis in 2008 could not
demonstrate an association between passive smoking and
the incidence of CD or UC.7
The numerous descriptive and epidemiological reports
on smoking and IBD are in sharp contrast with the limited
amount of mechanistic studies exploring the effect of ciga-
rette smoke on the gut and on intestinal inflammation in
particular. The molecular and cellular mechanisms by
which smoking interferes with the pathogenesis of CD and
UC are only partially understood. Although several potential
mechanisms, such as modulation of mucosal immune re-
sponses, alterations in intestinal cytokine and eicosanoid
levels or modifications in gut permeability have been pro-
posed, none of these hypotheses could offer a satisfying ex-
planation.8,9 Moreover, the exact component(s) of cigarettesmoke exerting the dual effect on CD and UC is not identified
up till now. Tobacco smoke contains more than 4500 chemi-
cals, many of them being toxic or interfering with the im-
mune system. Among these, nicotine, carbon monoxide
(CO) and nitrogen oxide are known to have immunomodula-
tory capacities and are possible mediators in IBD pathogene-
sis, but also other tobacco constituents can interact with
intestinal immunity and gut function.10
One of the problems the scientific world is facing in ex-
ploring the interaction between smoking and the gut, is the
difficulty to find a good model. On one hand, human studies
are complex and establishing a good study design with suffi-
cient power is demanding. Firstly, definitions of who is
considered a smoker or non-smoker are hard to make,
and smoke anamnesis is not always reliable. Furthermore,
numerous potential confounding factors have to be dealt
with, such as medication and social class. On the other
hand, in vitro studies in which cigarette smoke extract or
smoke constituents are administered to intestinal cell cul-
tures or cells isolated from IBD patients can be used. This
kind of experiment is easier to standardize and interfering
factors can be better controlled. However, in vitro exper-
iments stand far away of clinical reality. Findings of these
studies, although valuable, have to be interpreted conser-
vatively. A third possibility to investigate the relationship
between smoking and IBD is the use of animal models.
These offer the advantage of performing in vivo experi-
ments in easier controllable conditions than human stud-
ies. Although human active smoking is difficult to mimic
in laboratory conditions, several animal models exist
using smoke exposure or nicotine administration.
Despite the important role of smoking in pathological
conditions in the gut such as IBD and colorectal carcino-
ma,11,12 only a limited number of groups have applied
3these animal smoke models. In this review, we discuss the
different established animal smoke models used in intestinal
research, focusing on the different methods for simulation
of smoking and on the smoke-induced effect on healthy gut
tissue, intestinal inflammation and inflammation-associated
neoplasia. Finally we reflect on the mechanism(s) through
which smoking might interact with the small bowel and
colon in normal and inflammatory conditions.
2. Animal models investigating the effect of
smoke exposure on the gut
Several groups investigated the effect of cigarette smoke
or its components on normal jejunum, ileum and colon in an-
imal models. A wide range of methods has been applied
(Table 1).
2.1. Nicotine
A number of groups studied the effect of nicotine, assuming
that nicotine is the main active metabolite responsible for
the impact of smoking on the course of IBD.9 A wide range
of administration methods and doses are applied in the
models described below, making it difficult to compare
these studies with one another.
The best studied way of administration is orally through
addition of nicotine to the drinking water of animals. The
group of Eliakim performed several experiments with oral
administration of nicotine to mice or rats. This model was
applied to investigate the effect of nicotine on experimental
(entero)colitis.13–15 Also Sykes and Ghia orally administered
nicotine to investigate the effect on hapten-induced colitis
in rodents.16,17
Others injected nicotine subcutaneously or intraperitone-
ally. Zijlstra and Thomas examined the effect of subcutane-
ous nicotine administration on the rectal mucosa in rabbits
and ferrets.18,19 Van Dijk et al. combined both above-Table 1 Administration methods applied in animal smoke model
Smoke component Administration route
Nicotine PO, 12.5–250 μg/mL
PO, 5–100 μg/mL
PO, 20 μg/mL
PO, 10–60 μg/mL
SC, 0.5–2 mg/kg/day
SC, 0.3–2 mg/kg/day
SC, 7.5 mg/kg, 2/day
PO, 25–200 μg/mL followed by SC 200 μg/da
IP, 0.04–0.4 mg/kg
CO Inhalation, 250 ppm
Inhalation, 200 ppm
TCDD PO, 5 μg/kg
PO, 15 μg/kg
Cigarette smoke Inhalation, 5–40 puffs/day
Inhalation, 2–4% in air
Inhalation, 1:6 smoke:air ratio
CO: carbon monoxide, IP: intraperitoneally, PO: per os (orally), SC: sumentioned methods and treated mice with oral nicotine for
8 days followed by subcutaneous administration.20 Galitovs-
kiy and colleagues subcutaneously administered nicotine in
two murine models of hapten-induced colitis.21 Snoek et
al. gave mice daily intraperitoneal injections of nicotine
during the induction of experimental colitis.22
Notwithstanding their importance for unveiling some
parts of the puzzle on smoking and IBD, there are some con-
cerns about extrapolation of these data to a clinical context.
It can be questioned whether oral or parenteral administra-
tion is appropriate to mimic (human) smoke inhalation. Es-
pecially in the case of oral nicotine administration, a local
noxious effect on the intestinal epithelium and mucosal bar-
rier cannot be excluded.2.2. Other smoke components
A limited number of groups addressed other components
of cigarette smoke. The group of Plevy exposed mice to CO
to investigate its role in two colitis models.23,24 Also in
the study of Takagi CO inhalation was applied in a murine
model of colitis.25 A group from the University of Hong
Kong injected rats intraperitoneally with extracts of either
filtered cigarette smoke or used cigarette filters for three
consecutive days to examine the effect of various tobacco
smoke components on hapten-induced colitis.26 Finally,
the effect of pretreatment with an oral dose of 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), a dioxin compound of
cigarette smoke, was studied in experimental colitis.27,28
The above-mentioned methods undeniably enhance our
understanding about the effect of smoke exposure on the
gut. However, extrapolation of their results to the context
of human IBD demands some caution. Cigarette smoke is a
complex mixture of several thousands of products potentiat-
ing or counteracting one another, and administration of only
one of these components makes it difficult to draw conclu-
sions about the interaction between smoking and the gut.s for intestinal research.
Duration of exposure Animal Ref.
2–3 weeks
2 weeks
15 days
17 days
Mouse, rat
Rat
Mouse
Rat
13–15
16
17
29
2 weeks
10 days
5 days
Rabbit
Ferret
Mouse
19
18
21
y 8 days PO followed by 2 weeks SC Mouse 20
7 days Mouse 22
5 days–2 weeks
3 days
Mouse
Mouse
23,24
25
1 day
Day 1 and day 6
Mouse
Mouse
27
28
1–2 times/day, 17 days
1 h/day, 3–11 days
30 min 4/day, 24 weeks
Rat
Rat, mouse
Mouse
29
26,31–36
39
bcutaneously, TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin.
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Several research groups exposed animals to smoke of burning
cigarettes, which we believe approximates best to human
smoking.
Galeazzi et al. described a model in which rats inhaled
cigarette smoke in a specialized smoking chamber. This
allowed a rhythmic smoke inhalation, which is more compa-
rable to human smoking than continuous exposure.29 The
group of Cho applied a smoke model which was first reported
in 1996 for the study of the effect of cigarette smoke on gastric
ulceration.30 Rats or mice were placed in a smoking chamber
filled with a fixed concentration of cigarette smoke for 1 h
daily. This smoke model allowed one to study the effect of
smoking on experimental colitis induced by trinitrobenzene
sulfonic acid (TNBS),31–34 by 2,4-dinitrobenzene sulfonic acid
(DNBS)26,35 or by dextran sulfate sodium (DSS).36,37
In the above-mentioned models, animals were exposed for
only a relatively short time to cigarette smoke (3 to 17 days).
In contrast, Verschuere et al. applied a chronic smoke
model, created to investigate the role of smoke exposure in
chronic airway diseases.38 Mice were exposed to tobacco
smoke four times per day. After 24 weeks, carboxyhaemoglo-
bin in serum of smoke-exposed mice reached a level compara-
ble with that of human smokers (8.70±0.31% versus 0.65±
0.25% in air-exposed animals), suggesting that this model is
appropriate for mimicking chronic (active) smoking.39
Also these smoke models have limitations. Every group
uses its own protocol for smoke:air ratio, duration of expo-
sure and the number of puffs or cigarettes administered
per day. Moreover, different types of cigarettes (commer-
cially available versus standardized research cigarettes),
with varying amounts of toxic components are used. Stan-
dardization of smoke exposure procedures could make
comparison of these studies more feasible.3. Influence of smoke exposure on the normal
gut mucosa
Animal studies primarily investigating the effect of cigarette
smoke exposure on the normal intestine are relatively
scarce.18–20,39 However, other reports focusing on smokingTable 2 Effect of smoke or nicotine exposure on small bowel in
Parameter Effect
Macroscopy No difference
Histology No difference
Inflammatory cells Recruitment of T-cells and DC
Cytokine levels IL-6↗, IL-10↘
IL-1β =, TNF-α =, IFN-γ =, IL-6 =, TGF-β
Chemokine levels CCL9↗, CCL20↗
PGE2 ↘
Apoptosis ↗ in FAE, = in VE
Mucus constituents ITF =, MUC2 =
Luminal IgA =
ROM production iNOS activity ↗
CS: cigarette smoke, DC: dendritic cells, FAE: follicle-associated epith
intestinal trefoil factor, PGE2: prostglandin E2, ROM: reactive oxygenin intestinal inflammation models also describe their find-
ings on normal gut as secondary end points. Overall, the lit-
erature on the impact of smoke exposure on gut histology
and physiology presents conflicting results. In some cases,
the differences between reports can be explained by dissim-
ilarities in the methods of smoke simulation. In other cases,
a dual effect on small bowel versus colon can account for di-
vergence between reports (Tables 2 and 3).
3.1. Inflammatory cells and mediators
A first point of interest is the effect of smoking on inflam-
matory cells and mediators. There is a consensus that
smoke exposure and nicotine administration do not cause
macroscopical or histological damage nor inflammation in
the gut.13,14,19,29,31 Furthermore, most authors could not
demonstrate an impact on colonic myeloperoxidase (MPO)
activity, an index of neutrophil infiltration.29,31,40 Only
one report described a significant, albeit modest, increase
of colonic MPO activity after smoke exposure.32 Also CO in-
halation did not cause colonic damage nor changes in MPO
activity.25
Verschuere et al. reported a recruitment of various im-
mune cell types into Peyer's patches, such as dendritic
cells (DCs), CD4+ T-cells, CD8+ T-cells and regulatory
T-cells (Tregs). However, this was not associated with tissue
damage. The hypothesis is that tolerogenic cell populations
(Tregs and CD11b+ DCs) and inflammatory cell types (ef-
fector T-cells) reach a new equilibrium without inducing
inflammation. Furthermore, Peyer's patch chemokines CCL9
and CCL20, involved in chemotaxis of immune cells, showed
an increase in smoke-exposed mice.39
Cigarette smoke nor TCDD had any effect on intestinal IgA
production in healthy gut.28,39 Relatively few reports are
available on the effect of cigarette smoke or its components
on cytokine levels in the gut. Eliakim described a dual effect
on cytokines, with a decrease of colonic interleukin (IL)-2
but an elevation of IL-6 and a decline of IL-10 in the jejunum
following nicotine administration.40 The diminished expres-
sion of IL-10 following smoke exposure was confirmed in
ileal Peyer's patches, but inflammatory cytokine levels in
Peyer's patches were unaltered.39 Van Dijk reported a signif-
icant decrease of the inflammatory cytokines IL-1β andnormal conditions.
CS constituent Animal Ref.
Nicotine Mouse, rat 13,14
Nicotine Mouse, rat 13,14
CS Mouse 39
=, IL-10↘
Nicotine
CS
Rat
Mouse
40
39
CS Mouse 39
Nicotine Rat 14
CS Mouse 39
Nicotine Mouse 13
CS Mouse 39
Nicotine Rat 14
elium, IL: interleukin, iNOS: inducible nitric oxide synthase, ITF:
metabolite, VE: villous epithelium.
Table 3 Effect of smoke or nicotine exposure on colon in normal conditions.
Parameter Effect CS constituent Animal Ref.
Macroscopy No difference CS, nicotine, CO Mouse, rat, rabbit 13,14,19,25,29,31
Histology No difference CS, nicotine Mouse, rat, rabbit 13,14,19,29,31
MPO activity No difference
↗
CS, nicotine, CO
CS
Rat, mouse
Rat
25,29,31,40
32
Cytokine levels Il-2↘, IL-6 =, IL-10 =
IL-1β↘, TNF-α↘
TNF-α =
Nicotine
Nicotine
CO
Rat
Mouse
Mouse
40
20
25
PGE2 =
↗
Nicotine
CS
Rat, rabbit, mouse, ferret
Mouse
14,18,20,40
37
Apoptosis = CS Mouse 36,37
Mucus constituents ITF↗, MUC2 = Nicotine Mouse, rabbit 13,19
Luminal IgA = TCDD Mouse 28
ROM production ROMs =, XA activity =, iNOS activity =
SOD activity ↘, GSH =
CS, nicotine
CS
Rat
Rat
14,31,32
31,32
CO: carbon monoxide, CS: cigarette smoke, DC: dendritic cells, GSH: glutathione, IL: interleukin, iNOS inducible nitric oxide synthase, ITF:
intestinal trefoil factor, MPO: myeloperoxidase, PGE2: prostglandin E2, ROM: reactive oxygen metabolite, SOD: superoxide dismutase,
TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin, XA: xanthine oxidase.
5tumor necrosis factor (TNF) α in the colonic mucosa of mice
after nicotine treatment.20 Overall, these studies suggest
that smoke and nicotine exposure on one hand cause a de-
crease of the anti-inflammatory cytokine IL-10 in the small
bowel, but on the other hand attenuate inflammatory cyto-
kine levels in the colon. CO was not found to influence colon-
ic TNF-α levels. However, its possible impact on other
inflammatory and immunosuppressive cytokines was not
studied.25
Data on the impact on mucosal eicosanoids are inconsis-
tent and strongly depend on the type of smoke model used.
Nicotine exposure induced a significant decrease in jejunal
prostaglandin (PG) E2 generation but had no influence on
colonic PGE2.14,19,40 Data on the influence on rectal eicos-
anoid levels are conflicting. Zijlstra described a significant
decrease of various eicosanoids after nicotine treatment.
This possibly implicates a decreased protective capacity
in the rectum against inflammatory stimuli.19 However,
more recent reports of his group could not demonstrate
an effect of nicotine on rectal prostaglandins.18,20 In con-
trast with these data from nicotine models, increased co-
lonic concentrations of PGE2 and leukotriene B4 (LTB4)
were observed following smoke exposure.31,32,37 This
might be explained by the interaction of dioxins in ciga-
rette smoke with aryl hydrocarbon receptors in the colon,
inducing PGE2 production.41,42
3.2. Mucosal barrier and epithelial lining
Another focus is the impact of smoking on intestinal epithe-
lium and the mucosal barrier. Two groups investigated
the effect of cigarette smoke on intestinal epithelium.
Verschuere investigated the follicle-associated epithelium
(FAE) covering murine Peyer's patches, because this is con-
sidered to be the first affected region in early CD.43,44 Fol-
lowing smoke exposure, an increased apoptotic index in
the FAE was observed. In contrast, the neighboring ileal vil-
lous epithelium did not show induction of apoptosis. This
suggests that the FAE is more vulnerable to smoke-inducedapoptosis than the absorptive epithelium.39 Liu found no ef-
fect of smoke exposure on apoptosis in the colonic mucosa
nor the colonic epithelium, confirming that absorptive epi-
thelium is more resistant to the noxious effects of smoke
exposure.36,37
Only two studies addressed the influence of nicotine and
smoke exposure on protective peptides and the mucus
layer. Nicotine treatment did not affect jejunal or colonic
expression of the neuropeptide somatostatin or the mucin
MUC2. The effect on other mucus layer constituents was
dual; while nicotine induced expression of colonic intestinal
trefoil factor (ITF), no changes were seen in jejunal ITF.13
Nicotine affected the thickness of the adherent mucus
layer in the rectum, with a significant reduction of the
mucus layer in the low dose group but an increase in mucus
layer in the high dose group.19
3.3. Oxidative stress
Intestinal damage and inflammation are associated with ox-
idative stress, caused by reactive oxygen metabolites (ROMs)
such as superoxide and N-chloramines. ROMs are produced
by several biochemical pathways involving many enzymes,
such as xanthine oxidase (XO) and inducible nitric oxide
synthase (iNOS). On the other hand, antioxidant systems, in-
cluding superoxide dismutase (SOD) and low-molecular-
weight antioxidant molecules, such as reduced glutathione
(GSH), function as scavengers for free radicals and are cyto-
protective against oxidative damage (Fig. 1). In homeostatic
conditions, a delicate balance exists between oxidants and
anti-oxidants.
Cigarette smoke can interfere with this balance through
several mechanisms. Next to mediating the pathways that
generate endogenous ROMs, cigarette smoke also contains
a high concentration of ROMs itself, including nitric oxide
and superoxide in the gas-phase and semiquinone-radicals
in the tar-phase. Furthermore, it contains metal ions such
as iron, which allow the transformation of hydrogen perox-
ide to the highly reactive hydroxyl radical.45
Figure 1 Mechanisms of oxidative damage. Panel A shows the generation of reactive oxygen metabolites (ROMs). These metabo-
lites can be formed by an enzymatic reaction out of oxygen. However, several ROMS are also present in cigarette smoke (bold).
Panel B shows the production of reactive nitrogen metabolites. These are normally formed as a side product of the transforma-
tion of L-arginine into citrulline by NOS. But as is the case with ROMs, several nitrogen reactive metabolites are components of
cigarette smoke. The formation of highly reactive metabolites including superoxide anion, the hydroxyl radical and NO3
− result in
damage to DNA, lipids and proteins causing tissue damage. The green arrows indicate protective anti-oxidant pathways, which
decrease oxidative stress. GSH: gluthatione, GSSG: oxidized gluthatione, GPx: gluthatione peroxidase, iNOS: inducible nitric
oxide synthase, SOD: superoxide dismutase, XO: xanthine oxidase.
6 S. Verschuere et al.Cigarette smoke or nicotine exposure did not induce
changes in colonic ROM production, nor in colonic XA activity
or iNOS activity. However, jejunal iNOS activity increased
after nicotine administration, possibly pointing towards an
increased generation of nitric oxide and an elevated oxida-
tive stress in the small intestine.14,31,32 GSH levels in the
colon were not altered by smoke exposure, but colonic SOD
activity decreased significantly.31,32 This can implicate a de-
creased radical-scavenging ability of the colon after smoke
exposure, making the gut more susceptible for oxidative
damage to cells and organelles.4. The effect of smoking on gut inflammation
A variety of genetical and chemically-induced colitis models
were used to study the impact of smoke or nicotine exposureon gut inflammation (Table 4). Both models mimicking CD
and UC were studied.4.1. TNBS-induced colitis
A first model is the administration of a TNBS enema, result-
ing in a colitis type which shares more similarities with
human CD than with UC.21 This model was used repeatedly
by the group of Cho, in combination with passive smoke ex-
posure. They described a potentiating effect of cigarette
smoke on TNBS-induced colitis, with a dose-dependent in-
crease in macroscopical lesions, MPO activity and LTB4 and
TNF-α concentrations in the distal colon. Microscopically,
smoke-exposed rats showed more tissue damage and inflam-
mation in comparison to controls.31–34 A possible mechanis-
tic explanation of this effect involves increased oxidative
Table 4 Influence of cigarette smoke and cigarette smoke components on experimental (entero)colitis.
Inflammation model Smoke constituent Effect on intestinal inflammation Ref.
TNBS colitis Cigarette smoke Potentiating effect 31–34
SC nicotine Potentiating effect 21
PO nicotine Low dose: attenuating effect
High dose: potentiating effect or no effect
15,16
CO Attenuating effect 25
PO TCDD Attenuating effect 28
Iodoacetamide PO nicotine Jejunitis: potentiating effect
Colitis: attenuating effect
14
IL-10−/− mice PO nicotine Jejunitis: potentiating effect
Colitis: attenuating effect
13
CO Attenuating effect 23
DNBS colitis Cigarette smoke Attenuating effect
Potentiating effect
26,35
29
SC nicotine Attenuating effect 26
PO nicotine Potentiating effect 29
Oxazolone colitis SC nicotine Attenuating effect 21
DSS colitis Cigarette smoke No effect 36
PO nicotine Attenuating effect 17
IP nicotine No effect 22
PO TCDD Attenuating effect 28
TCRα−/− mice CO Attenuating effect 24
CO: carbon monoxide, DNBS: 2,4-dinitrobenzene sulfonic acid, DSS: dextran sulfate sodium, IP: intraperitoneally, PO: per os, SC: subcu-
taneous, TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin, TNBS: trinitrobezene sulfonic acid.
7stress due to smoke exposure. The effect of TNBS on iNOS ac-
tivity, on GSH concentration and on ROM production was ag-
gravated by cigarette smoke. In contrast, the TNBS-induced
rise in SOD and XO activity was attenuated by smoke expo-
sure, decreasing the anti-oxidant capacities.31,32
On the contrary, the other findings in this model
appeared to have rather a protective function than a damag-
ing role in intestinal inflammation. Smoke exposure had no
effect on TNBS-induced colonic PG synthesis, or on expres-
sion of cyclooxygenase (COX)-1, but potentiated expression
of COX-2. COX-2 is involved in the synthesis of PGs and exerts
a protective effect on mucosal damage in colitis.33 Further-
more, they demonstrated that cigarette smoke causes a
TNBS-independent increase in colonic expression of the α7
subunit of the nicotinic acetylcholine receptor (nAChR),
which is an essential regulator of inflammation by inhibiting
the release of TNF by macrophages.34,46
Galitovskiy and colleagues confirmed the aggravating ef-
fect on TNBS colitis by nicotine administration. They
reported a significantly higher DAI (disease activity index)
score and more severe colonic inflammation, as assessed
both macroscopically and microscopically. Moreover, nico-
tine caused a further increase of CD4+ T-cells in the lamina
propria of mice treated with TNBS. The Treg population
remained unaltered, whereas the Th17 T-cells additionally
increased after nicotine administration. Finally, nicotine po-
tentiated the TNBS-induced elevation of the inflammatory
cytokines IL-23 and IFN-γ.21
Also other groups used the TNBS model of experimental
colitis, but their findings conflicted with the data from
Guo and Galitovskiy. Both Eliakim and Sykes reported a de-
crease in the macroscopical lesion area, histological dam-
age and MPO activity in nicotine-treated TNBS colitis. Thepotentiating effect on LTB4 levels and the lack of impact
on PGE2 generation was confirmed.15,16 However, the ob-
served effect of nicotine on oxidative stress differed greatly
from the findings of Guo. Eliakim found no effect of nicotine
on TNBS-induced colonic NOS activity.15 Sykes et al. demon-
strated that nicotine attenuated the increase of iNOS and,
to a lesser degree, of TNF-α.16 Interestingly, both authors
reported that the attenuating effect of nicotine on TNBS-
induced inflammation and damage was more evident after
administration of a modest dose, while a high nicotine
dose had a smaller effect or even aggravated the induced
lesions.
CO inhibited TNBS colitis, as assessed both macroscopi-
cally and histologically. Furthermore, MPO activity and
TNF-α levels attenuated after CO inhalation.25
Finally, an amelioration of TNBS colitis was described
after administration of the dioxin TCDD, both clinically and
histologically. The effect of TCDD was mediated by aryl hy-
drocarbon receptor activation on immune cells, causing a
suppression of the inflammatory colonic cytokines IL-6,
TNF-α, IFN-γ and IL-12. In contrast, the colonic expression
of IL-10 and IL-17 remained unaltered. TCDD also generated
Tregs in TNBS colitis. So both a decrease in inflammatory
mediators and an increase in Tregs can account for the ame-
lioration of colonic inflammation in this model. Further-
more, TCDD was able to modulate humoral gut immune
responses in TNBS colitis, including an increase in IgA.28
Summarized, literature on the effect of cigarette smoke
and its components on TNBS-induced colitis revealed con-
flicting results. Two studies using nicotine administration
reported a dose-dependent effect on intestinal inflamma-
tion, so the inconsistent data can be explained to a certain
extent by differences in nicotine dosage and means of
8 S. Verschuere et al.administration. Furthermore, it appears that different
smoke components affect TNBS colitis in divergent ways,
leading to opposing results. This might explain the conflict-
ing epidemiological data on human CD colitis, with different
studies describing divergent outcomes of smoking and nico-
tine therapy on the disease course of CD colitis.8,47–49
4.2. Iodoacetamide-induced enterocolitis
A second animal model of chemical enterocolitis is the use of
iodoacetamide, inducing lesions mimicking CD. This model
not only investigated the colon but also the jejunum. Nico-
tine had diverging effects on inflammation in the small
bowel and the colon. Jejunitis aggravated, both macroscop-
ically and microscopically. Furthermore, jejunal NOS activi-
ty increased and PGE2 decreased, suggesting a role for
oxidative damage and decreased mucosal protection by PG
in the damaging effect of nicotine on small intestinal inflam-
mation. In contrast, colonic inflammation was attenuated by
nicotine, as assessed by lesion area and histological score.
Colonic NOS activity remained unchanged.14
4.3. Enterocolitis in IL-10−/− mice
The next model discussed is a genetical model, IL-10 defi-
cient (IL-10−/−) mice, which spontaneously develop chronic
enterocolitis with features similar to CD. After nicotine ad-
ministration, jejunitis deteriorated significantly, both gross-
ly and histologically, with more extensive and multifocal
lesions. In contrast, colitis in IL-10−/− mice ameliorated,
as could be appreciated both macro- and microscopically.
The protective effect on colitis can be modulated through
increased production of protective peptides and mucus com-
ponents. Colonic expression of ITF and somatostatin in-
creased significantly after nicotine administration, whereas
jejunal concentrations remained unchanged. Expression of
MUC2 was unaltered in both jejunum and colon.13
A second group investigated the effect of CO on colitis
in IL-10−/− mice. Histological improvement was observed,
together with decreased colonic levels of IL-12 p40 and
TNF. Unfortunately, the effect on the small bowel was not
studied.23
4.4. DNBS-induced colitis
A frequently used colitis model entails the administration
of a DNBS enema to induce a chemical colitis mimicking
UC rather than CD. Two groups used this model, but again
with conflicting results. Galeazzi investigated the impact
of both inhaled cigarette smoke and oral nicotine, and
reported a deterioration of DNBS colitis (both macroscopi-
cally and microscopically) and a potentiating effect on MPO
activity after smoke exposure. Nicotine administered in
high doses led to similar results.29
In contrast, Ko described an attenuation of DNBS colitis
by smoke inhalation as well as subcutaneously administered
nicotine. Furthermore, smoke and nicotine exposure down-
regulated the DNBS-induced increase of LTB4 levels and
concentrations of TNF-α, IL-1β and IL-6. Also induction of
ROM production and iNOS activity in DNBS colitis was
attenuated.26,35As both groups investigated smoke exposure as well as
nicotine treatment, it is unclear what causes the discrepan-
cies between these studies.
4.5. Oxazolone-induced colitis
One study examined the effect of nicotine on oxazolone co-
litis, a murine model mimicking UC colitis. Nicotine-treated
animals showed a decreased severity of colitis, as evaluated
by the DAI score and macroscopical and histological exami-
nation of the colon. Furthermore, nicotine further increased
the percentage of CD4+ T-cells in the colonic lamina propria.
When examining different lamina propria T-cell subsets, a
significant rise in Tregs was observed, whereas Th17 cells
tended to decrease following nicotine administration.
The authors hypothesized that the observed nicotine-
induced changes are mediated by nAChRs, causing alter-
ations in T-cell development and function and modifying
cytokine production. Indeed, oxazolone-exposed T-cells had
increased levels of α7 nAChRs. Consistent with this, nicotine
lost his attenuating effect on oxazolone colitis in α7 knock-
out mice, indicating that the α7 nAChR plays a crucial role in
the activity of nicotine.21
4.6. DSS-induced colitis
Snoek and colleagues used the acute model of DSS colitis to
study the effect of nicotine on an UC type of colitis. Nicotine
did not induce clinical improvement of colitis, as assessed by
clinical parameters and histopathological score. Although
colonic levels of the inflammatory cytokines IL-6 and IL-17
were significantly reduced following nicotine administra-
tion, no alterations in TNF levels were observed.22
The DSS colitis model was also applied by Liu et al. Their
results were comparable with the reported data of Snoek;
nor assessment of edema, nor pathological scoring of the
severity of inflammation could reveal differences between
the smoke-exposed and the control group.36
Also Ghia examined the effect of nicotine on DSS colitis.
However, the results of this study are in sharp contrast
with the two afore-mentioned reports. Nicotine was found
to decrease both macroscopical and microscopical damage,
as well as MPO activity. Furthermore, a decrease in TNF
and IL-1β was described, whereas IL-6 levels remained unal-
tered.17 Differences in administration ways may account for
the contradictory effects described in these studies, with
orally administered nicotine exerting not only a systemic ef-
fect, but also a local effect on the mucosal barrier.
Pretreatment with the dioxin TCDD inhibited DSS-induced
colitis, as assessed by decreased weight loss, reduced in-
flammation and lower levels of heme oxygenase-1 (HO-1),
MPO and TNF-α. Its effect is likely to be mediated through
induction of PGE2 production.27 However, also the genera-
tion of Tregs can partly account for the immunosuppressive
effect of TCDD.28
4.7. Colitis in TCRα−/− mice
A last model mimicking UC is a genetical model in which the
gene of TCRα is disrupted. These mice develop spontane-
ously colitis with a Th2 signature. When these mice were
9exposed to CO, a significant amelioration in body weight
and inflammation was observed. This was associated with
a decreased production of inflammatory cytokines, such as
IL-1β, IL-4, TNF and IL-17 and increased production of IL-
10 by colonic macrophages.24
Overall, CO appears to have a positive effect on cytokine
levels in every colitis model investigated. This effect is at
least partly HO-1 mediated.
5. Smoke exposure and inflammation-induced
carcinogenesis
An important pathway in the development of colorectal
carcinoma is inflammation-associated neoplasia. IBD, and
especially UC, is associated with an increased risk for devel-
opment of colorectal cancer. A correlation exists between
the extent and longevity of inflammation and the risk of
cancer.50,51 Also smoking is an independent risk factor for
colorectal neoplasia.11 However, smoking is considered as
a protective factor in UC as well, ameliorating the severity
and extent of colitis.9 Several authors suggested that
smoking protects against cancer in UC patients, although
no consensus exists on the role of cigarette smoke in in-
flammation-associated carcinoma in the colon.52,53
Liu et al. investigated whether smoke exposure counter-
acts the detrimental effect of colonic inflammation on carci-
nogenesis or, conversely, enhances inflammation-associated
neoplasia. Epithelial proliferation index did not increase im-
mediately after smoke exposure but was significantly higher
1 month later, pointing to a possible carcinogenic effect of
tobacco smoke in the pathogenesis of colorectal neoplasia.
Smoke exposure increased dose-dependently the incidence
of both dysplasia and carcinoma one month after DSS colitis.
Also the number of adenomatous polyps increased after cig-
arette smoke exposure. The authors suggest that although
cigarette smoke alone was not able to cause dysplasia, it
provides an abundant source of carcinogens. This increases
the risk for DNA repair errors during the rapid cell turnover
in the context of intestinal inflammation, resulting in a
higher number of mutant cells and replication errors in mu-
cosal regeneration.36,37
6. Translation of data from animal studies to a
clinical context
Valuable information can be deduced from the data discussed
above regarding the effect of smoke and its constituents
on both normal gut function and intestinal inflammation.
In physiological conditions, cigarette smoke does not
cause macroscopical or microscopical damage to the gut.
However, smoking appears to make the small intestine
more susceptible to events that trigger inflammation. The
small bowel becomes less tolerogenic with a decrease of
IL-1039,40 and a recruitment of inflammatory cells towards
the Peyer's patches.39 Furthermore, the concentration of
PGE2, which protects the gut against mucosal damage, de-
creases and a higher iNOS activity is observed, leading to
increased oxidative stress for the intestinal epithelium.14
In the colon, the impact of smoke exposure is less clear.
The colonic cytokine profile following smoke exposure ismore favorable, with a decrease in several inflammatory
cytokines.20,40 The increased expression of ITF is also a pro-
tective factor.13 However, the observed decrease in colonic
SOD activity is rather harmful, as this diminishes the scav-
enging capacity toward ROMs.31,32 In summary, the effect
of smoke and its constituents on the colon appears ambigu-
ous, whereas on the small bowel it is deleterious.
The interaction of tobacco smoke and its constituents
with experimental (entero)colitis is even more liable to
dual interpretation. Depending on the model for experimen-
tal inflammation applied, an aggravating or ameliorating ef-
fect is seen. Especially in TNBS- and DNBS-induced colitis,
the data from different groups are inconsistent. Various ex-
planations can be given for the divergent results discussed
in this review. First of all, in the different models a variety
of species were used. It is not established yet whether
these species react similarly towards smoke exposure. Sec-
ondly, smoke administration methods differ greatly, ranging
from inhalation of cigarette smoke and CO to orally or subcu-
taneously administered nicotine, applied in diverse doses
and during diverging time intervals. Thirdly, some authors
focus on the small bowel, while others investigate the
colon or both organs. Finally, different models of experi-
mental (entero)colitis were used to study the effect of ciga-
rette smoke on intestinal inflammation. Every IBD model has
its own strengths and weaknesses, and approximates more to
human CD or UC. In most studies, the effect of smoke expo-
sure on acute inflammation was considered, whereas the
IL-10−/− model and repeated DSS administration offer a
model for chronic relapsing inflammation, more resembling
human IBD. To make a comparison of the data from different
studies more feasible, standardization of smoke models in
gastrointestinal research is imperative. No data are avail-
able on the effect of smoking cessation on colonic inflamma-
tion. This would be interesting, given the increased risk to
develop UC after smoking cessation in humans.
The best studied cigarette smoke component is undeni-
ably nicotine. Nicotine is considered as an important media-
tor of intestinal inflammation with immunomodulating
capacities. Therapeutic use of nicotine is extensively studied
in human UC. However, conflicting data on the efficacy
and safety of nicotine treatment impede its implementation
in standard UC therapy.54,55 The mechanism through which
nicotine exerts its immunosuppressive effect, is most likely
the ‘cholinergic anti-inflammatory pathway’, a concept
first introduced by Tracey.56 This pathway modulates sys-
temic inflammatory responses through efferent vagal nerve
signaling. Hereby neurotransmitters, such as nicotine and
acetylcholine, interact with nAChRs on immune cells in pe-
ripheral organs.57 It was shown that nicotine signaling in-
hibits TNF release by human macrophages after triggering
with endotoxin, and this is modulated by interaction with
the α7 nAChR on macrophages.46,56 Cigarette smoke expo-
sure was demonstrated to increase colonic expression of
the α7 nAChR, and this might account for the protective ef-
fect of smoke or nicotine exposure on experimental colitis,
down-regulating TNF-induced inflammation.34 Interestingly,
a recent publication illustrated a dual effect of nicotine
in two different models of experimental colitis. This was
due to a differential expression of α7 nAChRs by colonic
T-cells. The Th2 cytokine milieu in oxazolone-induced colitis
facilitated expression of α7 nAChR, whereas the Th1-type
10 S. Verschuere et al.cytokines in TNBS colitis abolished α7 nAChR expression. In-
teraction of nicotine with this receptor skewed the Treg/
Th17 balance towards the immunosuppressive Tregs, result-
ing in attenuation of colonic inflammation and improvement
of the clinical condition. The results of this elegant study
can help to understand the opposing effects of smoking on
UC and CD.21
However, although nicotine unquestionably plays a major
role in the effect of smoking on the gut, there is no evidence
that it is the sole active mediator in cigarette smoke. To
some extent, nicotine and smoke exert the same effect on
the gut. However, other tobacco components also inter-
vene, augmenting or suppressing the influence of nicotine
on gut immunology and physiology. For example, the aryl
hydrocarbon receptor pathway is implicated in the preven-
tive effect of smoking on experimental colitis and UC. Ad-
ministration of TCDD, a dioxin component of cigarette
smoke, results in attenuation of colitis in several models
of experimental colitis (TNBS, DSS). Hypotheses on how
TCDD exerts its effect include induction of colonic PGE2,27Figure 2 Divergent effect of smoking on the small bowel and the
has a detrimental effect on the small bowel immunology, predispo
li.13,14,39,40 For the colon, more ambiguous effects are described in t
tinal commensal flora, viral or bacterial pathogens, and genetic
constituents will determine whether beneficial or rather unfavorabldown-regulation of inflammatory cytokines,28,58 and gener-
ation of Tregs.28 Therefore, we believe that no premature
conclusions should be drawn from animal studies adminis-
trating a sole smoke constituent.
Notwithstanding the differences between human active
smoking and the above-mentioned animal models mimicking
smoking, some interesting conclusions can be drawn for the
impact of smoking on human IBD. In the past, several hy-
potheses were formulated about the dual effect of smoking
on CD and UC. Some authors assumed that this difference
was due to disease type (Th1 response in CD versus Th2 re-
sponse in UC), causing a distinct cytokine milieu in which
the effects of the different smoke components can be mod-
ified.21 Others proposed that genetical predisposition,
resulting in divergent metabolism of smoke constituents,
played a role making an individual more vulnerable to
the immunosuppressive or immunogenic effect of individual
smoke components.59,60 A last hypothesis is that not the
disease type, but the disease location determines the ef-
fect of smoking. Small bowel disease, like Crohn's ileitis,colon. Evidence from animal models shows that smoke exposure
sing it towards increased vulnerability to inflammatory stimu-
he different models.13,20,31,32,40 Other factors, such as the intes-
predisposition manipulating the metabolism of various smoke
e effects will take over.
11is negatively influenced by cigarette smoke, whereas colon-
ic inflammation often ameliorates under smoke exposure.
In favor of this hypothesis is that literature describes a
worse outcome for Crohn's ileitis than for Crohn's colitis, al-
though also Crohn's colitis is negatively influenced by active
smoking.8,48 Indeed, when examining the current available
data on smoke animal models in IBD research, the divergent
effect of cigarette smoke on small bowel and colon is
confirmed. Whereas the small bowel appears to be driven
towards susceptibility for inflammatory stimuli and in-
creased risk for developing enteritis, the situation for
the colon is less clear. Cigarette smoke constituents
exert both immunosuppressive and immunogenic effects
on the colon, leading to respectively an attenuation or
aggravation of colitis. We hypothesize that the effect of
smoking on colitis depends on other factors, such as ge-
netical predisposition, cytokine environment and environ-
mental factors (Fig. 2). Further research will need to
elucidate the conditions in which cigarette smoke exerts
a beneficial or rather an injurious effect on colonic
inflammation.
7. Conclusion
What lessons can we learn from these animal models on
the impact of smoking on human gut in physiological and
pathological conditions? Smoking appears to have a diver-
gent effect on small bowel and colon, leading to a less tol-
erogenic phenotype in the small bowel and both beneficial
and damaging alterations in the colon. This dual effect on
the colon is also reflected in IBD models, giving conflicting
results about the impact of cigarette smoke on colitis,
whereas enteritis is negatively influenced by smoke expo-
sure in every animal model tested. Nicotine plays a modulat-
ing role in intestinal inflammation through interaction with
the α7 nAChR on intestinal immune cells. However, the im-
pact of other smoke compounds should not be neglected.
More and better standardized research will help to elucidate
the remaining questions on the exact role of smoking on the
gut in health and disease.
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